Leerink Partners Rates PROCEPT BioRobotics (PRCT) hold
Leerink Partners lowers its rating on PRCT to Hold with a $29 price target, a 12.82% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated PROCEPT BioRobotics Corporation ($PRCT) "hold" with a $29 price target on June 11, 2026.
Since the rating, $PRCT is down 21.6% after 1 week, down 23.4% after 1 month and down 36.5% to date (from the $27.69 close on Jun 11, 2026).
PRCT
PROCEPT BioRobotics Corporation
Key Points
- Leerink Partners downgraded PRCT to Hold with a $29 price target on June 11, 2026.
- Leerink Partners's $29 price target implies 12.82% upside from PROCEPT BioRobotics Corporation's ($PRCT) current $25.70 share price.
- PRCT shares are currently trading at $25.71, following the latest analyst ratings.
- Recent insider buying activity included purchases by multiple insiders on June 9, 2026.
Get $PRCT trade alerts by text
We text you when insiders, Congress or big funds trade $PRCT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated PROCEPT BioRobotics Corporation alert may contain errors. Disclosures
Leerink Partners has downgraded its rating on PRCT to a Hold, setting a price target of $29. This change was announced on June 11, 2026, as analyst Mike Kratky adjusted his outlook on the stock. PRCT shares were trading at approximately $25.71 at the time of the downgrade.
Other Institutional Activity in PRCT
Several other institutional investors have also made moves in PRCT recently. BlackRock, Inc. increased its holdings by 14,969 shares, bringing its total to about 4.36 million shares valued at $109.1 million. T. Rowe Price Investment Management, Inc. added 2,386 shares, holding a total of approximately 3.27 million shares worth $81.9 million. Meanwhile, BNP Paribas Asset Management Holding S.A. reduced its position by 5,271 shares, leaving it with around 3.09 million shares valued at $77.3 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated new positions with holdings of 2.42 million and 2.39 million shares, respectively.
PROCEPT BioRobotics Corporation Stock Up 33.2%
Shares of PRCT are currently trading near $25.71. The stock has been experiencing various levels of institutional interest, as evidenced by recent changes in holdings by major funds. The stock's performance and market interest are closely watched by investors and analysts alike.
$PRCT price target
PROCEPT BioRobotics Corporation daily closes and this analyst's $29 target. Not advice.
Insider Buying and Selling at PROCEPT BioRobotics Corporation
Recent insider activity at PRCT includes several purchases on June 9, 2026. Desai Antal Rohit, Amy Dodrill, Thomas Prescott, Dan Puckett, and Mary Garrett each acquired shares, with the transactions involving 3,315 to 5,853 shares per insider. These transactions were not made under a Rule 10b5-1 plan, indicating discretionary buying.
Analysts Set New Price Targets
On June 11, 2026, Leerink Partners downgraded PRCT to a Hold with a $29 price target. Previously, on April 30, 2026, Piper Sandler reiterated its Buy rating with a $35 target. Baird initiated coverage on March 6, 2026, with a Hold rating and a $30 target. The analyst consensus reflects a mixed outlook, with a blend of Hold and Buy ratings.
Bottom Line
The recent downgrade by Leerink Partners highlights a cautious stance on PRCT, with a new Hold rating and a $29 target. Institutional investors have shown varying degrees of interest, with some funds increasing their stakes while others trim positions. Insider buying activity suggests confidence among those close to the company. As always, investors should consider these factors in the context of their own investment strategies.
Related Filing Alerts
Source: Leerink Partners's rating change on $PRCT (Jun 11, 2026). Written by software, not financial advice. How we make alerts